OBJECTIVESTo investigate the effects of a number of variables on phoneme discrimination (PD) performance in children with sequential bilateral cochlear implants (SeqBiCIs) and compare PD performance between the 2 implantation sides and between children with bilateral cochlear implants (BiCIs) and their age-matched peers with normal hearing (NH).DESIGNAll participants completed the Auditory Speech Sound Evaluation Phoneme Discrimination Test.STUDY SAMPLEThe sample included 23 children with SeqBiCIs as the study group and 23 with NH as the control group.RESULTSA significant difference was found between the scores of the two groups under the CI₁ and CI₂ conditions (p = 0.001), CI₁ and BiCI conditions (p = 0.002), and CI₂ and BiCI conditions (p = 0.001). PD scores with CI₁ significantly depend on age at CI₁ and duration of bilateral use. PD scores with CI₁ were significant predictors of PD performance with CI₂. Duration of BiCI use was a significant predictor of PD scores with BiCI.CONCLUSIONSThe age at CI₁ and the duration of bilateral cochlear implant use were found to improve phoneme discrimination performance in children with a sequential bilateral cochlear implant. According to the success of the CI₁, it is possible to predict the success of CI₂ use.

01 Sep 2019·Otology & NeurotologyQ2 · MEDICINE

Speech Perception Growth Patterns in Prelingual Deaf Children With Bilateral Sequential Cochlear Implantation

Q2 · MEDICINE

Article

Author: Lee, Jee Yeon ; Kim, Yehree ; Kang, Woo Seok ; Lee, Je Yeon ; Park, Jun Woo ; Kwak, Min Young ; Ahn, Joong Ho ; Kang, Byung Chul ; Lim, Won Seob ; Park, Hong Ju ; Chung, Jong Woo ; Seo, Ji Won

Objective:To evaluate speech perception following the first (CI-1) and second (CI-2) cochlear implantation (CI) in children with sequential bilateral CI.Study Design:Retrospective.Patients:Seventy children with follow-up for 60 months post CI-1 and 36 months post CI-2.Main Outcome Measures:Word recognition score (WRS) was the main outcome. WRSs were compared by age at CI operation (group A ≤ 3.5 yr, B 3.6–8.6, for CI-1; group I ≤ 3.5 yr, II 3.6–7.0, III 7.1–13, IV > 13, for CI-2).Results:For CI-1, the WRS of group A exceeded 80% at 24 months post procedure, earlier than group B (54 mo). Group A also had a shorter period of CI-1 use up to the WRS plateau than group B. CI-2 showed an initial burst of WRS growth much earlier than CI-1. This initial burst was most robust within 3 months in group II, but modest in group IV. The periods of CI-2 use (11–17 mo) up to the WRS plateau were much shorter than CI-1 (40–64 mo). Group I did not show the best WRS at 1 month post CI but later exceeded the other groups.Conclusion:Children received an immediate benefit by a burst of WRS growth from CI-2 earlier than CI-1, even within 3 months, suggesting that CI-1 gets the auditory cortex ready to foster speech processing from CI-2. The CI-2 performance depends on age at CI-2 implantation and on CI-1 performance. Our current findings will be relevant for clinicians who are counselling parents on CI-2 surgery.

01 Sep 2001·Journal of EthnopharmacologyQ2 · MEDICINE

Effect of a herbal protein CI-1, purified from Cajanus indicus on the ultrastructural study of hepatocytes, in models of liver failure in mice

Q2 · MEDICINE

Article

Author: Sarmistha Datta ; Prantosh Bhattacharyya

Ultrastructural changes in acute liver damage models in swiss albino mice (male, 30 g +/-2) induced by CCl(4) (0.1 ml/100 g); beta-galactosamine (500 mg/kg); paracetamol (300-500 mg/kg) and 40% ethanol (2 ml/100 g) were studied. Electron microscopical studies of hepatocytes of treated (hepatotoxins) mice showed-dilation of ER of both rough and smooth type with swollen mitochondria. Ethanol treated mouse hepatocytes showed giant mitochondria and presence of balloon cells. Nuclear changes showed increase in size and striking anisonucleosis, especially in CCl(4) and paracetamol treated mouse hepatocytes. Condensation of chromatin, nucleoli were fragmented and dispersed in beta-galactosamine induced hepatotoxic mice. These changes are remarkably striking in contrast to control animals. Treatment with CI-1, the herbal protein isolated from Cajanus indicus inhibited the pathogenesis of a majority of lesions produced by the hepatotoxins. Slender mitochondria, array of granular ER, presence of binucleated cells are the salient features of CI-1 treated hepatotoxic mice. Ultrastructurally, the hepatocytes of CI-1 treated mice were near normal. Thus, the herbal protein CI-1, may be a useful approach in the treatment of liver disorders for its potential in clinical medicine.

100 Deals associated with CI-01(Biomap Intelligent)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	Preclinical	China	Biomap (Beijing) Intelligent Technology Co., Ltd.	25 Aug 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

CI-01(Biomap Intelligent)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation